Weight Management

Finding simple solutions to improve movement during the day can make important differences to their overall health

There are 2 features of weight loss interventions which are most likely to improve weight loss outcomes—having access to professional health coaches and social support from other users.

With the increase in counterfeit GLP-1 and GLP/GIP medications available online, education may be needed for patients around the dangers of unregulated medications.

Eli Lilly & Co. has been one of the first companies to address the off-label use of their tirzepatide drugs, Mounjaro and Zepbound, for cosmetic weight loss.

Liraglutide, a glucagon-like peptide 1 receptor agonist, has shown a clinically and significant reduction in glycated hemoglobin for those with type 2 diabetes.

With gastrointestinal-based adverse effectss for rivastigmine and other cholinesterase inhibitors, a weight of <50 and <55 kg respectively leads to an increased risk for toxicities.

This month's Pharmacy Times Condition Watch features obesity and type 2 diabetes.

In the phase 3 SURMOUNT-4 trial, investigators included individuals with at least 1 weight-related complication, including hypertension, dyslipidemia, obstructive sleep apnea, or cardiovascular disease.

A new hydrogel drug delivery system could change the way diabetes is managed.

Older treatments and novel options are changing the way obesity is treated and managed

The SELECT trial expands on existing literature that have shown safety and cardiovascular benefit in individuals with diabetes to now also show benefit in obesity.

Tirzepatide is already approved under the brand name Mounjaro (Lilly) to be used along with diet and exercise to improve blood sugar in adults with type 2 diabetes.

Pricing is also a key issue, as many insurance plans do not cover these medications’ use for obesity.

A low carbohydrate diet plus a sodium glucose contransporter-2 (SGLT2) inhibitor was found to be safe and effective for weight loss and glycemic control in patients with diabetes and chronic kidney disease.

This “refreshing alternative” to calorie restriction does not include calorie counting, yet it is naturally associated with greater energy restriction compared to the latter.

Semaglutide was found to be the most effective drug for weight loss, but the benefits may not outweigh the cost associated with treatment.

Long lasting weight reduction was reported in individuals that were treated with tirzepatide with diet and exercise, compared to placebo.

Latinx teens suffering with mental health issues are at risk of developing cardiovascular conditions in their future.

Obesity is a chronic disease comprised of dysregulated adipose tissue, increasing the risk of developing serious health conditions, and requires more than just losing weight.

Poor sleep patterns were related to anxiety, depression, body fat gain, and loss of muscle mass in older individuals who are obese.

SYNCHRONIZE-1, SYCHRONIZE-2, SYNCHRONIZE-CVOT will evaluate survodutide for overweight and obesity.

Harmful LDL functionality contributes to an increase of cardiovascular disease in those with obesity but could decrease within weight loss.

Current federal statutes exclude anti-obesity medications for coverage when used for anorexia, weight loss, or weight gain.

Only 1% of children experienced obesity remission and lower socioeconomic status was connected to a worsened trajectory.

In addition to identifying strategies to reduce the adverse effects of sleep and circadian disruption, the study authors identify the impact of obesity on sleep.

As a once-daily oral treatment, orforglipron could help address barriers to injectable medications, such as semaglutide and liraglutide.

Although GLP-1 receptor agonists have shown promise in promoting weight loss, they are prescription medications and should be used under the guidance of health care professionals.

Beyond its primary role in diabetes treatment, SGLT-2 inhibitors have demonstrated versatility in various health aspects, offering benefits beyond glucose reduction.

After 1 year of treatment, semaglutide significantly improved physical function, which can improve quality of life outcomes and risk of death.